Telix Pharmaceuticals (TLPPF) Current Deferred Revenue (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Current Deferred Revenue for 4 consecutive years, with $390000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $390000.0 in Q2 2026; TTM through Jun 2026 was $390000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $402000.0, down 94.23% from the prior year.
• Current Deferred Revenue was $390000.0 for Q2 2026 at Telix Pharmaceuticals, down from $402000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.4 million in Q4 2024 and troughed at $390000.0 in Q2 2026.
• A 4-year average of $3.8 million and a median of $3.8 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue rose 2.77% in 2024 and sank 94.53% in 2025, its largest moves.
• Over 4 years, Current Deferred Revenue stood at $7.2 million in 2023, then gained by 2.77% to $7.4 million in 2024, then slumped by 94.53% to $402000.0 in 2025, then decreased by 2.99% to $390000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $390000.0 (Q2 2026), $402000.0 (Q4 2025), and $7.4 million (Q4 2024), per Business Quant data.